Additionally, recent studies have demonstrated the enhanced level of IFN and the activation of IFN-related pathways in MetS patients, including the cyclic GMP-AMP synthase-stimulator of interferon genes signaling (cGAS-STING) pathways (47, 48). This evidence concerns the gene STING1 and metabolic syndrome.